EA
HRMY icon

Ellsworth Advisors’s Harmony Biosciences HRMY Stock Holding History

Ellsworth Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,699
Closed -$219K – 173
2023
Q1 		$219K Buy
6,699
+429
+7% +$19.5K 0.08% 154
2022
Q4 		$311K Buy
+6,270
New +$345K 0.12% 140

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ellsworth Advisors's HRMY Position: Q2 2023 in Review

Ellsworth Advisors sold out of Harmony Biosciences (HRMY) in Q2 2023, closing a stake of 6,699 shares — an estimated $219K sold.

Ellsworth Advisors first reported a position in HRMY in Q4 2022 and held it in 2 quarters. The position peaked at $311K in Q4 2022. 211 funds tracked by Wall St. Rank hold HRMY as of Q2 2023.

  • Ellsworth Advisors reported no remaining Harmony Biosciences position as of Q2 2023 after selling out during the quarter.
  • Ellsworth Advisors sold 6,699 Harmony Biosciences shares in Q2 2023, an estimated $219K.
  • Ellsworth Advisors first reported a position in Harmony Biosciences in Q4 2022 and held it in 2 quarters.
  • Ellsworth Advisors's Harmony Biosciences position peaked at $311K in Q4 2022.
  • 211 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2023.

Based on Ellsworth Advisors's 13F filing for Q2 2023, filed 24 Jul 2023.